2013
DOI: 10.4172/2329-6607.1000e105
|View full text |Cite
|
Sign up to set email alerts
|

Measuring Platelet Reactivity after Clopidogrel-Has it Reached the End of the Road?

Abstract: Clopidogrel is traditionally prescribed at 75 mg daily after a 300 mg loading dose. It is a pro-drug, with a two-step activation process involving a series of cytochrome P-450 (CYP) isoenzymes. Its antiplatelet effect is variable and susceptible to genetic polymorphisms. In particular, patients with either 1 or 2 loss-of-function CYP2C19 alleles have an attenuated pharmacologic response and worse clinical outcomes with standard dose clopidogrel [1]. Among clopidogrel-treated subjects in TRITON-TIMI 38, carrier… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
16
0

Year Published

2015
2015
2017
2017

Publication Types

Select...
5

Relationship

3
2

Authors

Journals

citations
Cited by 6 publications
(16 citation statements)
references
References 17 publications
0
16
0
Order By: Relevance
“…Clopidogrel is a pro-drug requiring a 2-step hepatic activation processes. Speed of activation varies according to the cytochrome P-450 2C19 allele [1,2]. Ticagrelor is a direct non-thienopyridine P2Y12 antagonist producing equal or stronger inhibition of the P2Y12 receptor even when compared to the newer thienopyridine prasugrel [3].…”
Section: Editorialmentioning
confidence: 99%
“…Clopidogrel is a pro-drug requiring a 2-step hepatic activation processes. Speed of activation varies according to the cytochrome P-450 2C19 allele [1,2]. Ticagrelor is a direct non-thienopyridine P2Y12 antagonist producing equal or stronger inhibition of the P2Y12 receptor even when compared to the newer thienopyridine prasugrel [3].…”
Section: Editorialmentioning
confidence: 99%
“…Relevant CYP isoenzymes involved in activating clopidogrel (and to a lesser extent prasugrel) may be affected by genetic polymorphisms which lead to different levels of their final active metabolites binding irreversibly to the platelet P2Y 12 receptors. For clopidogrel, patients with either 1 or 2 loss-of-function CYP2C19 alleles are known to have an attenuated pharmacologic response and worse clinical outcomes, with greater impairment in those who had both alleles affected [3].…”
Section: Why Antarctic Failed and What Remains For Tailored Antiplatementioning
confidence: 99%
“…The situation is different with the use of clopidogrel for which up to 40% of patients are somewhat resistant [4] with the occasional patients (often having 2 loss-of-function CYP2C19 alleles) actually having minimal platelet suppression and potentially unduly high risks of stent thrombosis. The latter situation should be remedied by switching clopidogrel to prasugrel or ticagrelor [3].…”
Section: Why Antarctic Failed and What Remains For Tailored Antiplatementioning
confidence: 99%
See 2 more Smart Citations